US Patent 11,690,826: Scope and Claims Analysis for Lotilaner Ophthalmic Methods for Demodex Blepharitis and Meibomian Gland Dysfunction
Executive summary: U.S. Patent 11,690,826 claims method-of-treatment regimens for Demodex-associated ocular disease using an ophthalmic composition containing lotilaner at ~0.25% by weight in a pharmaceutically acceptable vehicle, with administration directly to the ocular surface (and for the MGD claim also to eye/eyelids/eyelashes). The dependent claims lock down dosage form (eye drop), dose volume (25 to 50 µL per administration), and treatment duration/frequency (once daily for ≥4 weeks; twice daily for ≥6 weeks; multiple alternative twice-daily and three-times-daily schedules each tied to ≥90 days). The practical IP barrier is that design-arounds must avoid the claimed combination of (i) lotilaner content at/around 0.25% w/w, (ii) the Demodex therapeutic indication framing (blepharitis or Demodex infestation–caused MGD), and (iii) at least one of the defined dosing schedules/volumes.
What does US Patent 11,690,826 claim, and what is the core protection scope?
Core independent claim theme (Claim 1 and Claim 11):
US 11,690,826 protects topical ophthalmic treatment methods that combine:
- Target condition:
- Claim 1: Demodex blepharitis
- Claim 11: Meibomian gland dysfunction caused by Demodex infestation
- Administration site:
- Claim 1: directly to an ocular surface of one or more eyes
- Claim 11: directly to one or more of the eye, eyelids, or eyelashes
- Therapeutic composition:
- Ophthalmic composition including lotilaner + pharmaceutically acceptable vehicle
- Lotilaner concentration:
- lotilaner present at about 0.25% by weight of the total administered composition
- Method framing:
- “topically administering … an effective amount” (indefinite amount, but concentration and regimen are tightened in dependent claims)
Claim breadth reality:
- Composition definition is narrow in one dimension: concentration is fixed to about 0.25% w/w.
- The “effective amount” phrase leaves the exact daily mass of lotilaner flexible, but dependent claims still constrain per-dose volume and frequency/duration.
- The method is not limited to a specific manufacturing process or device. It is limited to use of a lotilaner-containing ophthalmic composition at the claimed concentration.
How do Claims 1-10 and 11-20 differ in clinical and infringement coverage?
Claims 1-10: Demodex blepharitis on ocular surface
- Claim 1 (independent): Demodex blepharitis; administration to ocular surface; ophthalmic composition with lotilaner ~0.25% w/w.
- Claim 2: composition is an eye drop.
- Claims 3-4: at least once daily for ≥4 weeks; 25–50 µL per administration.
- Claims 5-6: at least twice daily for ≥6 weeks; 25–50 µL per administration.
- Claims 7-8: at least twice daily for ≥90 days; 25–50 µL per administration.
- Claims 9-10: at least three times daily for ≥90 days; 25–50 µL per administration.
Net coverage pattern: The blepharitis set targets both shorter (≥4 weeks once daily) and longer maintenance/extended courses (≥90 days with higher cadence).
Claims 11-20: Demodex-caused MGD treated at eye/eyelid/eyelashes
- Claim 11 (independent): MGD caused by Demodex infestation; administration directly to eye/eyelids/eyelashes; ophthalmic composition with lotilaner ~0.25% w/w.
- Claim 12: eye drop.
- Claims 13-14: once daily for ≥4 weeks; 25–50 µL.
- Claims 15-16: twice daily for ≥6 weeks; 25–50 µL.
- Claims 17-18: twice daily for ≥90 days; 25–50 µL.
- Claims 19-20: three times daily for ≥90 days; 25–50 µL.
Net effect: Claims 11-20 parallel claims 1-10 but shift the anatomic scope and the disease causal framing (Demodex-caused MGD). From an infringement risk standpoint, this expands clinical reach because “eyelids/eyelashes” can capture treatment protocols that direct administration beyond just the ocular surface.
What specific dosing regimens are locked by the dependent claims?
The dependent claims create multiple “hard” regimen anchors. A single accused regimen can fall into multiple dependent claim categories if it matches frequency, duration, and volume.
Regimen matrix (as claimed)
| Claim set |
Frequency |
Minimum duration |
Dose volume per administration |
| Claims 3-4 |
≥1 time/day |
≥4 weeks |
25 to 50 µL |
| Claims 5-6 |
≥2 times/day |
≥6 weeks |
25 to 50 µL |
| Claims 7-8 |
≥2 times/day |
≥90 days |
25 to 50 µL |
| Claims 9-10 |
≥3 times/day |
≥90 days |
25 to 50 µL |
The same matrix applies to the MGD claims (13-14, 15-16, 17-18, 19-20).
Interpretation pressure points
- The phrase “at least” makes the claims effectively ceiling-free: a longer duration or higher frequency can still satisfy the “minimum” thresholds.
- The volume range 25–50 µL means design-around can target smaller or larger per-drop volumes only if that can be made to be outside the range in a way that is both reproducible and provable.
What does “lotilaner at about 0.25% by weight” mean for claim construction and design-around?
The concentration limitation is a major infringement driver.
Why the concentration is the key design constraint
- If an accused product uses materially different lotilaner concentration (e.g., 0.1%, 0.5%, or similar), infringement of the method claims is less likely because the claims require lotilaner present at about 0.25% by weight.
- If an accused product is still within the “about” range, then dosing regimen and indication framing become the next gating factors.
Practical claim-risk implications
- For licensing, the concentration limitation reduces the “free substitution” space in formulation negotiations.
- For litigation strategy, concentration is a clean technical fact to plead: label strength and analytical testing establish the basis.
Is this a formulation patent, a method patent, or both?
US 11,690,826 is primarily a method-of-treatment patent with composition elements used to define the administered product.
- The claims are written as methods (“method for treating…”), not as standalone composition claims.
- However, the method recites the administered ophthalmic composition compositionally (lotilaner + vehicle) and quantitatively (0.25% w/w lotilaner).
- The dependent claims also recite dosage form as an eye drop (Claims 2 and 12).
Infringement focus: Accused activity would likely be alleged as patient treatment using a lotilaner 0.25% eye drop under the claimed Demodex indications and regimen.
What are the likely infringement theories for each claim family?
Claims 1-10 (Demodex blepharitis)
- Product-supplied usage theory: prescribing or administering an eye drop containing lotilaner ~0.25% with regimen matching one of the dependent schedules.
- Labeling/Instructions-to-Use alignment: if patient instructions specify dose volume and frequency, that can map to the dependent claims.
Claims 11-20 (Demodex-caused MGD)
- Indication-based practice: requires that the MGD is framed/treated as caused by Demodex infestation. That means clinical documentation, physician diagnosis coding, or IFU language can matter.
- Administration site expands the possible factual record because administration can be directed at eyelids/eyelashes, not just ocular surface.
How would a generic or “follow-on” lotilaner eye drop avoid infringement?
Because the claims combine (i) concentration, (ii) product type (eye drop), and (iii) regimen thresholds, a viable design-around must disrupt at least one of those pillars.
High-impact design routes
- Concentration deviation: change active concentration so it does not meet about 0.25% w/w.
- Regimen mismatch: change frequency/duration so it falls below each minimum threshold for the accused course.
- Volume mismatch: change per-administration volume so it does not fall within 25 to 50 µL.
- Indication reframing: avoid use expressly framed as treating Demodex blepharitis or Demodex-caused MGD.
Lower-impact routes
- Merely changing vehicle composition is unlikely to avoid the claims because the claims require only “pharmaceutically acceptable vehicle” and do not restrict its chemistry.
- Minor changes to anatomic positioning may not help unless they avoid “ocular surface” (Claim 1) or the eyelid/eyelash inclusion (Claim 11).
What does this claim set imply about Orange Book status and ANDA risk?
Method-of-treatment claims can be listed against a reference drug in the Orange Book if they were submitted as patents claiming the drug (including certain use claims). For ANDA strategy, the key is whether these claims are treated as enforceable barriers via Orange Book listing and whether they are challenged under Paragraph IV.
Risk structure for ANDA entrants:
- If the reference product is a lotilaner 0.25% eye drop and these claims are Orange Book-listed, ANDA filers face Paragraph IV exposure premised on infringement of the listed method claims.
- The regimen and dose-volume limitations can be used by both sides: a generic can argue labeling or administration differences defeat infringement; the patent holder can argue typical prescribing practices match the claimed regimen.
When does exclusivity end versus when do patent claims expire?
This question cannot be answered fully from the claim text alone. A precise timeline requires the patent’s issued and prosecution history dates and any related patent term adjustments, maintenance status, and any co-pending exclusivity periods. Without those, the exclusivity and expiration calendar cannot be produced accurately.
What can be concluded from the claim text: the claims are standard U.S. utility method-of-treatment claims; they do not, by themselves, disclose expiry or exclusivity end dates.
Which other patents typically surround Demodex lotilaner ophthalmic assets?
US 11,690,826’s claims indicate an adjacent landscape likely exists in three clusters:
- Core active and composition concentration patents
- Patents covering lotilaner use/derivatives and formulation concentration.
- Dosing regimen and method-of-use patents
- Multiple claims that vary by frequency/duration, anatomic site, and clinical endpoint framing (blepharitis vs MGD).
- Ophthalmic formulation and manufacturing patents
- Stabilization, delivery system attributes, drop volume reproducibility, and manufacturing processes.
A litigation or licensing posture must treat US 11,690,826 as one layer in a likely stacked estate. The claimed concentration and dosing parameters suggest other claims may exist that are either broader (covering more schedules) or narrower (covering particular dose volumes or duration cutoffs).
Comparative risk: how does the blepharitis set compare to the MGD set?
Coverage difference:
- Blepharitis claim set requires treatment of Demodex blepharitis with administration to ocular surface.
- MGD claim set requires MGD caused by Demodex infestation with administration to eye, eyelids, or eyelashes.
Infringement leverage:
- If a clinical program targets both indications, the estate can support multiple infringement narratives.
- If an accused product’s intended use is only ocular surface (not eyelids/eyelashes), MGD claims may be harder to map factually, though the “eye/eyelids/eyelashes” language can still be satisfied if administration instructions direct placement at those sites.
What does the claim structure suggest about how the patent holder will litigate?
Key elements to plead and prove
- Lotilaner concentration at about 0.25% w/w (analytical testing and label).
- Product form is an eye drop if the dependent claims are asserted.
- The dosing regimen: minimum frequency, duration, and volume per dose.
Most efficient asserted claim strategy
Patent holders often assert the strongest dependent claims that match the accused IFU and real-world administration. Here, the regimen and volume dependencies provide a tight factual fit if the accused treatment matches a common dosing program.
Key Takeaways
- US 11,690,826 protects method-of-treatment regimens for Demodex blepharitis and Demodex-caused MGD using an ophthalmic lotilaner eye drop with lotilaner ~0.25% w/w.
- Dependent claims tightly constrain dose form (eye drop), per-administration volume (25–50 µL), and treatment schedules (once daily ≥4 weeks; twice daily ≥6 weeks; and longer-course schedules ≥90 days at twice daily or three times daily).
- For design-arounds, the highest-impact levers are changing lotilaner concentration outside “about 0.25%,” using dosing regimens that miss all minimums, and avoiding patient treatment practices that map to the defined volume and frequency.
- The claim set is structured to support enforcement against products and labeling that align with a typical clinical dosing course for Demodex-associated ocular disease.
FAQs
1) Can a product with a different lotilaner concentration still infringe US 11,690,826?
Infringement depends on whether the accused product’s lotilaner strength meets the claim requirement of about 0.25% by weight. If it is materially different, the claim’s concentration limitation is not satisfied.
2) Does the patent require proof of Demodex infestation by testing?
The claims require treating diseases defined by Demodex presence or infestation framing. Proof typically flows from clinical diagnosis and treatment documentation, aligned with the asserted claim’s indication wording.
3) If a competitor uses the same 0.25% eye drop but shortens treatment below 90 days, can it avoid the longer-course claims?
If the accused regimen does not meet the minimum duration/frequency thresholds of the asserted dependent claims, those specific claims may be avoided. However, shorter dependent schedules may still be implicated depending on regimen.
4) Are claims 1 and 11 limited to “drops” administered by a specific device?
No. The claims require an eye drop in the dependent claims, but they do not recite a specific device. The core limitation is the composition and regimen.
5) What is the biggest factual battleground in enforcement of the dependent claims?
The dose volume (25–50 µL) and treatment cadence/duration are the most concrete regimen facts, paired with confirmation of lotilaner concentration in the administered product.
References
- United States Patent 11,690,826 (claims provided by user).
